Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for [225Ac]Ac-AKY-1189 (AKY-1189) in Nectin-4 expressing solid tumors. The expected timing is based on the latest available company guidance and may change.
6/3/26- NECTINIUM-2 Ph1b ongoing in Nectin-4 expressing solid tumors; prelim data in Q1 2027. FDA Fast Track granted in locally advanced/metastatic urothelial cancer. 08/13/26:- Enrollment continued in the Phase 1b NECTINIUM-2 trial. Preliminary data are expected in Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.